PI3K Inhibitors for CLL
A comparison of 3 PI3K inhibitors—idelalisib, duvelisib, and umbralisib—as treatment for chronic lymphocytic leukemia.
Novel Therapies for CLL in the Context of COVID-19
What to know in terms of COVID-19 vaccine responses in patients with chronic lymphocytic leukemia on novel targeted therapies.
Chemotherapy-Free Regimens as Frontline Therapy in CLL
Key takeaways of the CLL13 (GAIA) clinical trial based on highlights presented at ASH 2021.
Fixed-Duration Therapy in Relapsed/Refractory CLL: Ibrutinib Plus Venetoclax
Considerations for treating patients with relapsed/refractory chronic lymphocytic leukemia with the combination of ibrutinib and venetoclax.
Frontline Therapy for CLL: Treatment Selection Based on Patient and Treatment Factors
Variables that impact which Bruton tyrosine kinase inhibitor is most appropriate as frontline therapy for patients with newly diagnosed chronic lymphocytic leukemia and the role of patient and disease factors in treatment selection.
Ibrutinib Therapy for CLL: Long-Term Data
Reactions to longer-term follow-up data presented in 2021 on the use of ibrutinib as frontline treatment for patients with chronic lymphocytic leukemia.
BTK Inhibitors as Frontline Therapy for CLL
The rationale for using Bruton tyrosine kinase inhibitors, such as the first-generation option, ibrutinib, as first-line treatment for chronic lymphocytic leukemia.
Dr Ganesan on the Use of ctDNA Assays For MRD Detection in Cancer Care
Dr Habib on Developments in Palliative Care For Patients With Cancer
Dr Boland on the Emergence of KRAS G12C Inhibitors in mCRC
Dr In on the Increased Incidence of Gastric Cancer in Minority Patient Populations
2 Clarke Drive Cranbury, NJ 08512